This weekend, the US House of Representatives passed its version of health care reform and now awaits a version from the Senate.  The debate has been heating up since earlier this summer when President Obama was pushing for legislation before the summer recess.  Here are the biggest S&P Health Care gainers and losers over while the debate has waged on.   Read More

Following are the day’s biggest winners and losers. Find out why shares of Nike and Huntington Bancshares popped while Biogen and Saks dropped.   Read More

With new data showing that consumers are unlikely to help spark growth anytime soon, can the market sustain its recent gains?   Read More

Biotech companies continued their rally today, with the biotech index up more than 35 percent in the last three months. Eric Schmidt, biotech analyst at Cowen, and Joel Sendek, managing director and biotech analyst at Lazard Capital Markets, explained the force behind the comeback and the best stock plays for investors right now.    Read More

Big money managers can instill confidence in individual stocks and you may be able to profit off their moves. Karen Finerman breaks down the holdings of the major money managers.   Read More

Carl Icahn and all of the Elanians should be happy. Biogen Idec today reported encouraging trends regarding its all-important multiple sclerosis drug Tysabri.    Read More

Brent Wilsey, president of Wilsey Asset Management, and Rod Smyth, chief investment strategist of Riverfront Investment, shared their economic outlooks and advised investors how to seek maximum profits.    Read More

Investors are placing their bets ahead of a string of pharma earnings due both this week and next. What must you know?   Read More

In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer.    Read More

Before I give you the high-tension, high-drama, high-intrigue details of the Biogen Idec shareholder meeting, it's best to just right from the get-go to let you know a spokesperson for the biotech company said, "No comment," about what's going down.    Read More